Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors

被引:26
作者
An, Ji-Hun [1 ]
Lim, Changjin [1 ]
Kiyonga, Alice Nguvoko [1 ]
Chung, In Hwa [2 ]
Lee, In Kyu [2 ]
Mo, Kilwoong [2 ]
Park, Minho [1 ]
Youn, Wonno [3 ,4 ]
Choi, Won Rak [3 ,4 ]
Suh, Young-Ger [1 ]
Jung, Kiwon [1 ]
机构
[1] CHA Univ, Inst Pharmaceut Sci, Coll Pharm, Sungnam 13844, South Korea
[2] Sungwun Pharmacopia, R&D Ctr, Seoul 05836, South Korea
[3] Chungbuk Natl Univ, Coll Pharm, Chungbuk 28644, South Korea
[4] Chungbuk Natl Univ, Med Res Ctr, Chungbuk 28644, South Korea
关键词
mirabegron; co-amorphous; active pharmaceutical ingredient; aqueous solubility; ionic interaction; SOLID-STATE NMR; PHYSICOCHEMICAL PROPERTIES; MECHANICAL ACTIVATION; BINARY-SYSTEMS; DRUGS; CIMETIDINE; INDOMETHACIN; DISPERSIONS; MIXTURES; ACID;
D O I
10.3390/pharmaceutics10030149
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, the screening of Mirabegron (MBR) co-amorphous was performed to produce water-soluble and thermodynamically stable MBR co-amorphous with the purpose of overcoming the water solubility problem of MBR. MBR is Biopharmaceutics Classification System (BCS) class II drug used for the treatment of an overreactive bladder. The co-amorphous screening was carried out by means of the vacuum evaporation crystallization technique in methanol solvent using three water-soluble carboxylic acids, characterized by a pKa difference greater than 3 with MBR such as fumaric acid (FA), l-pyroglutamic acid (PG), and citric acid (CA). Powder X-ray diffraction (PXRD) results suggested that all solid materials produced at MBR-FA (1 equivalent (eq.)/1 equivalent (eq.)), MBR-PG (1 eq./1 eq.), and MBR-CA (1 eq./1 eq.) conditions were amorphous state solid materials. Furthermore, by means of solution-state nuclear magnetic resonance (NMR) (H-1, C-13, and 2D) and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, we could assess that MBR and carboxylic acid molecules were linked via ionic interactions to produce MBR co-amorphous. Besides, solid-state cross polarization (CP)/magic angle spinning (MAS) C-13-NMR analysis was conducted for additional assessment of MBR co-amorphous. Afterwards, dissolution tests of MBR co-amorphouses, MBR crystalline solid, and MBR amorphous were carried out for 12 h to evaluate and to compare their solubilities, dissolution rates, and phase transformation phenomenon. Here, the results suggested that MBR co-amorphouses displayed more than 57-fold higher aqueous solubility compared to MBR crystalline solid, and PXRD monitoring result suggested that MBR co-amorphouses were able to maintain their amorphous state for more than 12 h. The same results revealed that MBR amorphous exhibited increased solubility of approximatively 6.7-fold higher compared to MBR crystalline solid. However, the PXRD monitoring result suggested that MBR amorphous undergo rapid phase transformation to crystalline form in just 35 min and that within an hour all MBR amorphous are completely converted to crystalline solid. Accordingly, the increase in MBR co-amorphous' solubility was attributed to the presence of ionic interactions in MBR co-amorphous molecules. Moreover, from the differential scanning calorimetry (DSC) monitoring results, we predicted that the high glass transition temperature (T-g) of MBR co-amorphous compared to MBR amorphous was the main factor influencing the phase stability of MBR co-amorphous.
引用
收藏
页数:14
相关论文
共 33 条
[1]   Towards Physico-Relevant Dissolution Testing: The Importance of Solid-State Analysis in Dissolution [J].
Aaltonen, Jaakko ;
Rades, Thomas .
DISSOLUTION TECHNOLOGIES, 2009, 16 (02) :47-54
[2]  
Alessio B., 2015, EP Patent, Patent No. [2857389A1, 2857389]
[3]   Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: Amorphous naproxen-cimetidine mixtures prepared by mechanical activation [J].
Alleso, Morten ;
Chieng, Norman ;
Rehder, Soenke ;
Rantanen, Jukka ;
Rades, Thomas ;
Aaltonen, Jaakko .
JOURNAL OF CONTROLLED RELEASE, 2009, 136 (01) :45-53
[4]   Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns [J].
Bates, Simon ;
Zografi, George ;
Engers, David ;
Morris, Kenneth ;
Crowley, Kieran ;
Newman, Ann .
PHARMACEUTICAL RESEARCH, 2006, 23 (10) :2333-2349
[5]   Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation [J].
Chieng, Norman ;
Aaltonen, Jaakko ;
Saville, Dorothy ;
Rades, Thomas .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (01) :47-54
[6]   PHARMACEUTICAL APPLICATIONS OF SOLID DISPERSION SYSTEMS [J].
CHIOU, WL ;
RIEGELMAN, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1971, 60 (09) :1281-+
[7]   Recent advances in co-amorphous drug formulations [J].
Dengale, Swapnil Jayant ;
Grohganz, Holger ;
Rades, Thomas ;
Lobmann, Korbinian .
ADVANCED DRUG DELIVERY REVIEWS, 2016, 100 :116-125
[8]   Characteristics and significance of the amorphous state in pharmaceutical systems [J].
Hancock, BC ;
Zograf, G .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1997, 86 (01) :1-12
[9]   MOLECULAR MOBILITY OF AMORPHOUS PHARMACEUTICAL SOLIDS BELOW THEIR GLASS-TRANSITION TEMPERATURES [J].
HANCOCK, BC ;
SHAMBLIN, SL ;
ZOGRAFI, G .
PHARMACEUTICAL RESEARCH, 1995, 12 (06) :799-806
[10]   Applications of solid-state NMR to pharmaceutical polymorphism and related matters [J].
Harris, Robin K. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 (02) :225-239